Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Grant # 1R21 AT003862-01A2 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Jarrow Formulas Inc | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Heart disease is the most common cause of death in the United States and it is commonly found in people with diabetes and high cholesterol. Inflammation is one mechanism by which diabetes and elevated cholesterol damage blood vessels. Inflammation can be increased by oxidative stress. This study will see if Alpha Lipoic acid, a potent antioxidant and over the counter product, reduces blood levels of markers of oxidative stress and inflammation when compared with placebo. Placebo is a substance that looks like the real product, but contains no active product.
This is a randomized study. A randomized study means you will be assigned by chance (like the toss of a coin) to one of four groups and receive either alpha lipoic acid (ALA or placebo (an inactive substance that looks like the real drug). In this study, there is a 1 out of 4 chance you will receive placebo. Three of the groups will receive different doses of ALA and one group will receive placebo only. The groups are: placebo only, 600 mg ALA, 1200 mg ALA, and 1800 mg ALA a day. At some point all study participants will receive placebo; sometimes the pills will be ALA and sometimes they will be placebo. You will not know which you are taking on any given day.
This study is also double-blinded, which means that you, the study doctor, and the Sponsor will not know until the end of the study whether you are receiving ALA or placebo only. Your study doctor can find out if you are receiving ALA or placebo if needed in an emergency.
If you agree to be in this study, you will be asked to come in for up to 6 visits in 12 weeks. You should be fasting before some of these visits. Fasting means that you should have nothing to eat or drink, except water with your usual morning medications, for 10 hours before your scheduled study visit. The study staff will go over this with you each time.
Visit 1-Screening: (about 3 hours)
• Please fast before this visit
In order to find out if you qualify to take part in the study, you will have the following tests and procedures done during this visit including:
The GTT test involves collecting 1 blood sample before, and 4 samples up to 2 hours after, you drink a measured amount of glucose (a sugar) in a pleasant tasting liquid. You will have 2 tablespoons of blood drawn. An indwelling intravenous (IV) needle will be inserted into your vein for the 2-hour period so that individual needle sticks will not be needed.
Depending on the results of your blood and urine tests, you may be asked to come in for a second visit in about 1 week. The screening blood tests may provide you with information on your health that could be important to you, for example diagnosing diabetes.
VISIT 2: (about 1 hour)
• You do not have to fast for this visit and may take your morning medications as usual
You will have the following tests and procedures done during this visit including:
- You will meet with a dietician for an assessment of your eating habits. The dietitian will advise you on how to maintain a stable diet during the study.
All unused study drug should be returned when you come in for the next visit in 2 weeks. It is important that you are able to take all the study drug. If we find that you are unable to take most of the study drug, you will be removed from the study.
VISIT 3: (about 6-8 hours)
•
Visit 4: telephone call. You will also be asked about your ability and willingness to continue to take the study medicine until the end of the study.
We will also ask if you are having any new symptoms that may indicate low blood sugar such as hunger, shakiness, dizziness, confusion, difficulty speaking, feeling anxious or weak.
You should notify the study team at any time by telephone to report these symptoms. You may be asked to come in for an extra visit if these are occurring.
Visits 5(day 1 and 2 final visits): (about 4 hours each day for 2 days)
• Please be fasting and do not have alcohol or exercise for 48 hours prior to these visits. You may be asked to withhold some of your usual medicines on both days but bring the doses to the visit with you to take at a later time.
These 2 visits may be done on 2 consecutive mornings.
Visit 5 day 1
You will have a brachial artery ultrasound with nitroglycerine, a DEXA scan, a 2 hour GTT blood test with an indwelling IV needle in your vein, height, weight, blood pressure.
- If you are a woman who can have children, you will be given a urine pregnancy test. If you are pregnant, you will NOT be able to have the DEXA scan that is part of this visit.
Visit 5 day 2
The brachial ultrasound will be repeated after a high fat meal is eaten which is provided by the study center.
You will have blood samples taken before and after the test and you will also meet with a dietitian for a final food questionnaire.
- You will return any unused study drug bottles.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| placebo | Placebo Comparator | Placebo 2 tabs three times daily |
|
| Alpha lipoic acid 1 | Experimental | Alpha lipoic acid 600 mg daily |
|
| Alpha lipoic acid 2 | Experimental | Alpha Lipoic acid 1200 mg daily |
|
| Alpha lipoic acid 3 | Experimental | Alpha lipoic acid 1800 mg daily |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Alpha lipoic acid at 3 doses compared to placebo | Dietary Supplement | This is a randomized study comparing the antioxidant effects of 3 doses of alpha lipoic acid (total of 600 mg daily, 1200 mg daily and 1800 mg daily) compared to placebo. These doses will be taken as 2 pills 3 times a day for 8 to 10 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| This study will provide information on the effect of a dose range of ALA on oxidative stress biomarkers. | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| To determine whether ALA improves vascular function through its effects on oxidative stress | 3 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pamela Ouyang, MBBS | Johns Hopkins University | Principal Investigator |
Not provided
| ID | Term |
|---|---|
| D024821 | Metabolic Syndrome |
| D018149 | Glucose Intolerance |
| D006973 | Hypertension |
| D009765 | Obesity |
| D006937 | Hypercholesterolemia |
| D056128 | Obesity, Abdominal |
| ID | Term |
|---|---|
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| D009750 |
| Nutritional and Metabolic Diseases |
| D006943 | Hyperglycemia |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |